NASDAQ:SEEL - Seelos Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.20
  • Forecasted Upside: 623.40 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$1.41
▲ +0.01 (0.71%)

This chart shows the closing price for SEEL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Seelos Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SEEL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SEEL

Analyst Price Target is $10.20
▲ +623.40% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Seelos Therapeutics in the last 3 months. The average price target is $10.20, with a high forecast of $14.00 and a low forecast of $8.00. The average price target represents a 623.40% upside from the last price of $1.41.

This chart shows the closing price for SEEL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Seelos Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/21/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/19/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/18/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/17/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/27/2021Roth CapitalUpgradeNeutral ➝ Buy$2.50 ➝ $8.00High
8/18/2021B. RileyLower Price TargetBuy$15.00 ➝ $11.00Medium
8/10/2021Roth CapitalLower Price TargetNeutral$4.00 ➝ $2.50High
7/1/2021GuggenheimInitiated CoverageBuy$8.00High
6/1/2021Cantor FitzgeraldInitiated CoverageOverweight$10.00High
5/17/2021Roth CapitalDowngradeBuy ➝ NeutralHigh
3/30/2021B. RileyInitiated CoverageBuy$15.00High
3/11/2021BTIG ResearchInitiated CoverageBuy$14.00High
9/28/2020Roth CapitalReiterated RatingBuy$12.00High
6/23/2020Roth CapitalBoost Price TargetBuy$8.00 ➝ $12.00High
11/18/2019HC WainwrightBoost Price TargetBuy$2.00 ➝ $4.00High
11/14/2019BenchmarkInitiated CoverageBuy$4.00High
8/2/2019Roth CapitalSet Price TargetBuy$8.00Low
5/14/2019Roth CapitalInitiated CoverageBuy ➝ Buy$8.00High
5/10/2019HC WainwrightInitiated CoverageBuy$4.00High
(Data available from 1/17/2017 forward)

News Sentiment Rating

0.33 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/21/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/20/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/19/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/18/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/18/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/17/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Seelos Therapeutics logo
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. The firm's portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior in Major Depressive Disorder �or Post-Traumatic Stress Disorder, �amyotrophic lateral sclerosis, Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases. The company was founded by Raj Mehra in 2016 and is headquartered in New York, NY.
Read More

Today's Range

Now: $1.41
Low: $1.35
High: $1.43

50 Day Range

MA: $1.74
Low: $1.40
High: $2.29

52 Week Range

Now: $1.41
Low: $1.35
High: $6.60

Volume

1,633,202 shs

Average Volume

2,013,210 shs

Market Capitalization

$144.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.74

Frequently Asked Questions

What sell-side analysts currently cover shares of Seelos Therapeutics?

The following sell-side analysts have issued stock ratings on Seelos Therapeutics in the last year: B. Riley, BTIG Research, Cantor Fitzgerald, Guggenheim, Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for SEEL.

What is the current price target for Seelos Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Seelos Therapeutics in the last year. Their average twelve-month price target is $10.20, suggesting a possible upside of 623.4%. BTIG Research has the highest price target set, predicting SEEL will reach $14.00 in the next twelve months. Roth Capital has the lowest price target set, forecasting a price of $8.00 for Seelos Therapeutics in the next year.
View the latest price targets for SEEL.

What is the current consensus analyst rating for Seelos Therapeutics?

Seelos Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SEEL will outperform the market and that investors should add to their positions of Seelos Therapeutics.
View the latest ratings for SEEL.

How do I contact Seelos Therapeutics' investor relations team?

Seelos Therapeutics' physical mailing address is 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022. The company's listed phone number is (646) 293-2100 and its investor relations email address is [email protected] The official website for Seelos Therapeutics is www.seelostherapeutics.com.